Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Bi-lateral HGN Therapy in Real-World Patients -Post Approval Research Investigation

NCT: NCT07331285 · RECRUITING

NCT IDNCT07331285
StatusRECRUITING
Start Date2026-06
Completion2032-10
SponsorNyxoah Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The objective of the BREATHE study is to demonstrate the continued safety and effectiveness of the Genio® System in treating subjects diagnosed with moderate to severe obstructive sleep apnea (OSA) who are intolerant to or failed/refused PAP treatments.

Frequently Asked Questions

What is Bi-lateral HGN Therapy in Real-World Patients -Post Approval Research Investigation?

Bi-lateral HGN Therapy in Real-World Patients -Post Approval Research Investigation is a clinical trial registered under NCT07331285. Current status: RECRUITING.

What is the status of NCT07331285?

The current status of NCT07331285 (Bi-lateral HGN Therapy in Real-World Patients -Post Approval Research Investigation) is: RECRUITING.

When did Bi-lateral HGN Therapy in Real-World Patients -Post Approval Research Investigation start?

Bi-lateral HGN Therapy in Real-World Patients -Post Approval Research Investigation started on 2026-06.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.